Clinical data | |
---|---|
Trade names | Fycompa |
Other names | E2007 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614006 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Anticonvulsant (AMPA receptor blocker)[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 116%[6] |
Protein binding | 95–96% |
Metabolism | Hepatic, mostly via CYP3A4 and/or CYP3A5 |
Elimination half-life | 105 hours, 295 hours (moderate hepatic impairment) |
Excretion | 70% faeces, 30% urine |
Identifiers | |
| |
Chemical and physical data | |
Formula | C23H15N3O |
Molar mass | 349.393 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Perampanel, sold under the brand name Fycompa, is a medication used to treat partial seizures and generalized tonic-clonic seizures.[5] It maybe used in addition to other medications or by itself.[8][7] It is taken by mouth.[7]
Common side effects include sleepiness, irritability, nausea, weight gain, and poor coordination.[7] Other side effects may include homicidal or suicidal thoughts, drug reaction with eosinophilia and systemic symptoms (DRESS), and abuse.[5] It also reduced the effectiveness of birth control containing levonorgestrel.[5] Use during pregnancy may harm the baby.[9] It works by blocking the AMPA receptor.[1]
Perampanel was approved for medical use in the United States and Europe in 2012.[8][5] In the United Kingdom 4 weeks of medication costs the NHS about £140 as of 2021.[10] This amount in the United States costs about 1,000 USD.[11] It is a Schedule III controlled substance by the Drug Enforcement Administration.[5]
References edit
- ^ a b Chong DJ, Lerman AM (April 2016). "Practice Update: Review of Anticonvulsant Therapy". Current Neurology and Neuroscience Reports. 16 (4): 39. doi:10.1007/s11910-016-0640-y. PMID 26984292. S2CID 9090302.
- ^ "AusPAR: Perampanel hemisesquihydrate". Therapeutic Goods Administration (TGA). 10 May 2021. Archived from the original on 13 June 2021. Retrieved 12 June 2021.
- ^ https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=52B9101BC60D00B2CA25867E003CC743&agid=(PrintDetailsPublic)&actionid=1[permanent dead link]
- ^ "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 2021-06-13. Retrieved 2021-09-13.
- ^ a b c d e f g h "Fycompa- perampanel tablet Fycompa- perampanel suspension". DailyMed. Archived from the original on 13 June 2021. Retrieved 12 June 2021.
- ^ Yang X, Wu TC, Yuxin MA, Lee JY, Bhattaram VA, Mehta MU. "U.S. FDA Clinical Pharmacology Review. Fycompa (perampanel)" (PDF): 25. Archived (PDF) from the original on 2017-05-06. Retrieved 2021-09-13.
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ a b c d "Perampanel Monograph for Professionals". Drugs.com. Archived from the original on 13 June 2021. Retrieved 27 October 2021.
- ^ a b "Fycompa". Archived from the original on 19 October 2021. Retrieved 27 October 2021.
- ^ "Perampanel (Fycompa) Use During Pregnancy". Drugs.com. Archived from the original on 29 October 2020. Retrieved 27 October 2021.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 340. ISBN 978-0857114105.
- ^ "Fycompa Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 17 January 2021. Retrieved 27 October 2021.